This means that it could be used in combination with GLP-1s to possibly enhance weight loss or simply offer an alternative to these drugs. Second, and one reason why someone might choose a CB1 drug ...

CB1 receptor antagonists, such as the aforementioned rimonabant and taranabant, were found to regulate food intake and adipose tissue metabolism, resulting in weight loss and favorable blood lipid ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

There is currently no approved treatment for PWS. CB1 inverse agonists have been shown to reduce appetite, and induce weight loss by several mechanisms, including increasing energy expenditure and ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The ...

Skye Bioscience (SKYE) announced preliminary data from a diet-induced obesity model in mice. Skye’s CB1-inhibiting antibody, nimacimab, ...

Novo and Lilly are also working on oral weight loss drugs. In September, Novo released phase 2b data on monlunabant, a cannabinoid receptor 1 (CB1) inverse agonist, though the results appeared to ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 ...

The third quarter marked an important transition for Skye as a metabolic-focused company with the launch of our Phase 2 obesity clinical trial for nimacimab. We believe our truly ...